Quick Facts

• Therapeutic Domain: Benign prostatic hyperplasia (BPH)
• Primary Benefit: Supports the management of urinary signs and symptoms
• Target Population: Adult males with BPH

---

What UroXatral Treats: Main Uses and Benefits

UroXatral (alfuzosin hydrochloride) is a medication utilized in the care plan for adult men experiencing benign prostatic hyperplasia (BPH), also known as an enlarged prostate. Its therapeutic domain focuses on managing the associated signs and symptoms that affect the lower urinary tract.

This medicine is an option to provide support for patient comfort by addressing urinary issues that may include difficulty initiating the flow of urine, experiencing a weak stream, or sensing the urgent and frequent need to urinate. By acting on specific receptors in the lower urinary tract, UroXatral may facilitate the outflow of urine, contributing to a better quality of life for individuals with BPH. UroXatral is indicated for the treatment of these signs and symptoms of benign prostatic hyperplasia. It is not intended for the treatment of high blood pressure or for use in the pediatric population. Its use is part of a comprehensive management strategy for BPH.

Eligibility Scope for UroXatral (Alfuzosin)

Official regulatory documentation strictly defines the eligible population and conditions under which UroXatral can and cannot be used. The medicine is indicated solely for adult males experiencing symptoms of benign prostatic hyperplasia (BPH).

---

Populations and Conditions for Whom Use is Contraindicated

Category	Regulatory Status
Hepatic Function	Contraindicated in patients with moderate or severe hepatic impairment (liver problems).
Hypersensitivity	Contraindicated for those with a known allergy to alfuzosin, quinazoline derivatives, or any component of the tablet.
Concomitant Use	Contraindicated with other alpha-1 adrenergic blocking agents or potent CYP3A4 inhibitors.

---

Age-Related and Conditional Restrictions

UroXatral is not indicated for use in women or in the pediatric population (children and adolescents) as its safety and efficacy have not been established in these groups. Use is not recommended in patients with severe renal impairment (severe kidney problems) due to limited safety data. The medicine requires caution when used in patients with a history of symptomatic postural hypotension or those with a risk of QTc prolongation.

UroXatral (alfuzosin) can interact with a wide variety of other medications, potentially leading to increased side effects, most notably severe low blood pressure (hypotension) or fainting (syncope), or increased blood levels of UroXatral itself.

Contraindicated Combinations (Do Not Take Together)

Due to the risk of serious or life-threatening reactions, UroXatral must not be taken with:

• Potent CYP3A4 Inhibitors: Medications that strongly block the enzyme responsible for metabolizing (breaking down) alfuzosin, leading to dangerously high drug levels. Examples include certain antifungal agents (e.g., ketoconazole, itraconazole), and some HIV protease inhibitors (e.g., ritonavir, atazanavir).
• Other Alpha-Blockers: Other drugs in the same class as UroXatral (e.g., doxazosin, prazosin, tamsulosin, terazosin) should be avoided as they increase the risk of severe hypotension.

---

Combinations Requiring Caution

Consult your healthcare provider regarding concomitant use with the following, as they require careful monitoring:

Category	Potential Interaction Risk
Phosphodiesterase-5 (PDE5) Inhibitors	Increased risk of symptomatic low blood pressure (e.g., sildenafil, tadalafil, vardenafil).
Antihypertensive Medications	Increased risk of low blood pressure when combined with drugs like beta-blockers, diuretics, or calcium channel blockers.
Nitrates	Increased risk of low blood pressure.
QT-Prolonging Drugs	UroXatral may slightly increase the risk of a serious heart rhythm issue (QT prolongation) when used with other drugs that have this effect (e.g., some antiarrhythmics, antibiotics).

Grapefruit juice should also be avoided as it can increase the concentration of alfuzosin in the blood.

Targeted Blockade of the Alpha-1 Adrenoceptors

Alfuzosin's core action is the competitive antagonism of post-synaptic alpha-1 adrenoceptors ( alpha1-AR ), which are densely located in the smooth muscle of the prostate, bladder neck, and prostatic urethra. By preventing the binding of the neurotransmitter Norepinephrine to these receptors, Alfuzosin interrupts the cellular signaling cascade that initiates muscle contraction, which is the foundational step in its mechanism.

Modulating Autonomic Smooth Muscle Tone

This blockade directly dampens the Sympathetic Nervous System's signal that governs muscle tension in the urinary outflow tract. This molecular event leads to the relaxation of the smooth muscle and subsequent reduction of functional resistance at the bladder outlet. This physiological adjustment of muscle tone is the direct consequence of the drug's mechanism.

Sustained Receptor Engagement and Consistency

Alfuzosin is formulated for extended release, a design that ensures the continuous and stable release of the active molecule into the system. This sustained delivery maintains consistent receptor blockade, resulting in a stable physiological modulation of muscle tension and resistance.

Official Administration Guidelines

UroXatral is administered as a 10 mg extended-release tablet intended strictly for oral use. The standard adult regimen requires the tablet be taken once daily (QD). This fixed dose establishes a standardized frequency for maintaining consistent therapeutic concentration.

To ensure the medicine is properly absorbed, the tablet must be taken with food and with the same meal each day. This consistency in daily intake is integral to supporting the optimal absorption of the drug.

The specialized formulation of the tablet necessitates careful handling. The tablet must be swallowed whole with sufficient fluid and must never be chewed, crushed, split, or otherwise divided. Altering the structure of the extended-release tablet can lead to an unintended, rapid release of the active ingredient, disrupting the intended 24-hour dosing schedule.

The 10 mg once-daily tablet serves as the maintenance dose, and no dose titration is typically required. For populations such as older adults, the same dose is generally applied without routine adjustment. However, the use of this formulation is not indicated for the pediatric population, and its use is restricted in patients with severely impaired kidney function or moderate-to-severe liver impairment.

If a dose is missed, the standard procedure is to skip the forgotten dose entirely and resume the normal once-daily schedule at the next scheduled time; a double dose should not be taken to compensate.

Research Evidence / Overview of Studies

UroXatral (alfuzosin) is an alpha-1 adrenergic antagonist primarily studied for the signs and symptoms of Benign Prostatic Hyperplasia (BPH). Clinical trials, including randomized, placebo-controlled studies, have focused on measuring the compound's effect on urinary symptoms and flow.

Research on Lower Urinary Tract Symptoms (LUTS)

Studies evaluating the 10 mg once-daily formulation have shown that treatment is associated with changes in core metrics of BPH.

• Symptom Score Improvement: In pooled analyses of double-blind, placebo-controlled trials, participants receiving alfuzosin generally exhibited greater improvement in the International Prostate Symptom Score (IPSS) compared to those on placebo.
• Urinary Flow Rate: Research also observed an increase in the peak urinary flow rate (PFR) in treated patients, suggesting changes in the rate of urine passage.

Safety and Tolerability Profile

Clinical trials observed the compound's tolerability profile in adult participants, noting that it was generally well tolerated, with withdrawal rates due to adverse events being comparable to placebo in some short-term studies.

Observation Category	Trial Findings
Cardiovascular Effects	No significant difference was observed in overall blood pressure changes compared to placebo, including in elderly or hypertensive patients.
Sexual Function	Studies generally report a low incidence of sexual adverse events, such as abnormal ejaculation.
Common Events	The most frequently reported events included dizziness and headache.

Specific Populations and Long-Term Data

Long-term observational studies conducted outside the initial registration trials have explored the maintenance of symptom improvement for periods up to two years. Research suggests that certain patient factors, such as the presence of intravesical prostatic protrusion (IPP), may be associated with a varied response to treatment.

Common questions about UroXatral (FAQ)

---

Q: How quickly does UroXatral usually start working?

Clinical trials have indicated that patients experienced changes in their urinary symptoms after starting treatment with UroXatral. The drug’s extended-release formulation is designed to release the medicine slowly and maintain stable levels over 24 hours, which is intended to provide a stable physiological modulation.

---

Q: Is UroXatral the same kind of medicine as Flomax?

UroXatral (alfuzosin) and Flomax (tamsulosin) both belong to the same class of medications, known as alpha-blockers. Regulatory documents note that UroXatral is contraindicated (should not be used) in combination with other alpha-blockers.

---

Q: Is UroXatral a medication that helps shrink the prostate?

The medication is indicated for relieving symptoms by relaxing the smooth muscles in the prostate and bladder. Official research indicates that this type of drug is a symptomatic treatment and does not typically cause the prostate gland to shrink.

---

Q: Do you have to take UroXatral forever once you start?

This medication manages the symptoms of BPH but is not a cure. Official information advises that treatment should continue as prescribed. The medication should only be discontinued under the guidance of a healthcare provider.

---

Q: Does UroXatral interact with herbal supplements?

Regulatory patient information advises informing a healthcare provider about all medicines being used, including prescription drugs, over-the-counter products, vitamins, and any herbal supplements, when treatment is initiated.

---

Q: What is the purpose of the extended-release formulation of UroXatral?

The extended-release formulation is a design intended to release the active ingredient into the body slowly and consistently. This controlled release over 24 hours is intended to maintain stable medication levels throughout the day.

---

Q: Why do official documents mention something about QT prolongation with UroXatral?

Official labeling notes that UroXatral has been associated with changes to the QT interval, a measure of the electrical activity of the heart. The regulatory label notes this potential effect, particularly when used in combination with other drugs known to affect the QT interval.

---

Q: Do older men need a lower dose of UroXatral?

Clinical studies involving individuals aged 65 and older did not show overall differences in safety or effectiveness compared to younger subjects. Official product information notes that no dose adjustment is routinely specified based on age alone.

---

Q: Why is UroXatral not approved for women?

Regulatory documents state that the medication is not indicated (approved) for use in women. Its approved purpose is for the treatment of Benign Prostatic Hyperplasia (BPH).

---

Q: How long does the effect of one UroXatral tablet last?

UroXatral is an extended-release medicine that is intended for once-daily dosing. The medication is designed to provide effects that last for approximately 24 hours between doses.

---

Q: What is the general success rate mentioned in UroXatral studies?

Official regulatory information reports that clinical trials indicate that patients taking the medication generally exhibited greater improvement in BPH symptom scores and an increase in peak urinary flow rate compared to placebo.

---

Q: Are there long-term safety concerns with using UroXatral?

Official labeling includes information about certain serious risks identified in clinical trials and post-marketing experience. These include Intraoperative Floppy Iris Syndrome (IFIS), which may occur during cataract surgery, and the potential for a prolonged, painful erection (priapism).

---

Q: Can UroXatral affect lab test results, such as PSA?

Regulatory information notes that this medication, like other alpha-blockers, may cause a modest decrease in Prostate-Specific Antigen (PSA) levels. This factor should be considered by a healthcare provider when interpreting a patient’s PSA test results.

---

Q: Is UroXatral a controlled substance?

No, UroXatral (alfuzosin) is not classified as a controlled substance by regulatory agencies in the United States.

---

Q: What are the signs of an allergic reaction to UroXatral?

Official labeling lists known hypersensitivity reactions, which may include hives (urticaria) and swelling of the face or throat (angioedema). Hypersensitivity to the drug is noted as a contraindication.

---

Q: Is UroXatral gluten-free or lactose-free?

Regulatory patient information contains warnings about the possible presence of excipients (inactive ingredients) like lactose. This makes the medication unsuitable for individuals with certain hereditary sugar intolerances, such as Lapp lactase deficiency.

---

Q: Can UroXatral be used in men with kidney impairment?

Caution is advised regarding its use in individuals who have severe renal impairment (a condition characterized by very low creatinine clearance). This caution is listed in the official prescribing information.

---

Q: Is it okay to drink alcohol in moderation while taking UroXatral?

Alcohol is listed as having a moderate interaction with UroXatral. Official labeling indicates that concomitant use may increase the risk of side effects, such as low blood pressure (hypotension) and dizziness.

---

Q: Does UroXatral interact with antacids?

Official labeling lists that certain ingredients found in some antacids or acid-reducing medications have the potential to interact with UroXatral. The interaction may be related to effects on heart rhythm or electrolyte balance.

---

Q: Can I stop taking UroXatral suddenly if I feel better?

Official patient information states that the medication should only be discontinued under the guidance of a healthcare provider.

---

Q: Is UroXatral a cure for prostate enlargement?

The medication is approved to help manage the symptoms of benign prostatic hyperplasia (BPH) by relaxing the prostate muscles. Official information describes UroXatral as a treatment for symptoms, not a cure for prostate enlargement itself.

---

Q: Are there any age restrictions for using UroXatral?

Regulatory information explicitly states that UroXatral is not indicated for use in the pediatric population (children). Its safety and effectiveness have not been established in this age group.

---

Q: Does UroXatral cause weight gain?

Weight gain is not listed as a frequently reported adverse reaction in the clinical trial or post-marketing experience sections of the official product labeling for UroXatral.

---

Q: Is UroXatral suitable for people who have had a heart attack?

Official labeling states that caution is advised regarding its use in individuals with pre-existing heart conditions. Certain cardiovascular events, such as angina pectoris (chest pain), have been reported in the post-marketing setting in patients with pre-existing coronary artery disease.

---

Q: Is UroXatral used for painful urination?

UroXatral is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). This can include various lower urinary tract symptoms, such as difficulty or discomfort during urination.

---

Q: What should I do if my BPH symptoms get worse while taking UroXatral?

Official patient counseling advises that individuals should inform their healthcare provider if their BPH symptoms worsen while using the medication, as this may require further evaluation.

How to Store and Dispose of UroXatral (Alfuzosin Extended-Release Tablets)

Storage Requirement	Official Condition
Temperature	Store at controlled room temperature, 20^circ-25 C (68^circ-77 F).
Protection	Store away from excess heat, moisture (not in the bathroom), and light.
Container	Keep in the original container, and keep it tightly closed.
Child Safety	Keep out of the reach and sight of children; use a safe, locked location.
Handling	Do not chew or crush the extended-release tablets to maintain integrity.

Disposal Instructions

To dispose of unused UroXatral, the preferred method is to use a community drug take-back or mail-back program. If a program is not available, mix the tablets (removed from their container) with an undesirable substance, such as used coffee grounds or cat litter. Place this mixture in a sealed bag or can and throw it in the household trash. Do not flush this medication down a toilet or sink unless specific instructions on the label advise otherwise.